Business Wire

bit.bio Launches New Custom Disease Model Cells Offering, Advancing Disease Research and Drug Discovery

Researchers can now order their mutation of choice in bit.bio’s opti-ox TM powered human-iPSC derived cells, receiving consistent, defined, cryopreserved products that can be immediately incorporated ...
Business Wire

bit.bio Launches Two New Human Cell Disease Models to Advance Discovery and Development of Treatments for Duchenne Muscular Dystrophy (DMD)

CAMBRIDGE, England--(BUSINESS WIRE)--bit.bio, the company coding human cells for novel cures, today launches its first set of muscle cell disease model products designed to advance the discovery and ...
BioWorld

Immorta’s dual-platform strategy doubles lifespan in aging models

Immorta Bio Inc. has reported new data demonstrating that its combination therapy of Senovax, a first-in-class senolytic immunotherapy, and personalized mesenchymal stem cells (pMSCs) from its ...
BioTechniques

Improved preclinical drug studies with next-generation in vitro cancer models

Accurate cancer models are integral to the success of preclinical research yet have proven elusive. Mindy Goldsborough (ATCC, VA, USA) discusses the ongoing efforts to develop improved in vitro models ...
BioTechniques

PDX models: tips, tricks and trends in cancer research

Alana Welm (left) is the Senior Director of Basic Science at the Huntsman Cancer Institute (University of Utah, UT, USA). Her lab studies breast cancer and its metastasis – the main cause of death for ...